Table 1.
Pre-treatment clinical characteristics and treatment regimens (n = 466a, HR+/HER2−)
| NCT (n = 405) | NET (n = 61) | p value | |
|---|---|---|---|
| Median age, years (range) | 51 (22–79) | 71 (43–88) | <0.001 |
| Pre- and perimenopausalb | 196 (48) | 5 (8) | <0.001 |
| Postmenopausalc | 209 (52) | 56 (92) | |
| T1/T2 | 268 (66) | 47 (77) | 0.091 |
| T3/T4 | 137 (34) | 14 (23) | |
| Clinically LN+ | 254 (63) | 16 (26) | <0.001 |
| Grade 1/2 | 197 (49) | 51 (84) | <0.001 |
| Grade 3 | 190 (47) | 6 (10) | |
| Grade unknown | 18 (4) | 4 (7) | |
| Invasive ductal carcinoma | 336 (83) | 43 (70) | 0.001 |
| Invasive lobular carcinoma | 46 (11) | 17 (28) | |
| Other | 23 (6) | 1 (2) | |
| ER status (IHC)+ | 388 (96) | 61 (100) | 0.146 |
| PR status (IHC)+ | 316(78) | 54 (89) | 0.063 |
| MammaPrint low risk | 95 (23) | 20 (33) | |
| MammaPrint high risk | 310 (77) | 41 (67) | |
| BluePrint Luminal A type | 95 (23) | 41 (67) | |
| BluePrint Luminal B type | 224 (55) | 19 (31) | |
| BluePrint HER2 type | 1 (<1) | – | |
| BluePrint Basal type | 85 (21) | 1 (2) | |
| AC-T or TAC | 175 (43) | – | |
| ddAC—T | 113 (28) | – | |
| TC | 65 (16) | – | |
| AC | 16 (4) | – | |
| Other NCT regimen | 36 (9) | – | |
| Anastrozole | – | 34 (56) | |
| Letrozole | – | 15 (25) | |
| Tamoxifen | – | 7 (11) | |
| Exemestane | – | 2 (3) | |
| Other | 3 (5) |
Significant values are given in bold at p ≤ 0.05
Data are expressed as n (%) unless otherwise specified
a8 Patients had NCT and NET
bPre- and perimenopausal: 6–12 months since last menstrual period
cPostmenopausal: >12 months since last menstrual period or bilateral oophorectomy/hysterectomy
ER estrogen receptor, PR progesterone receptor, IHC immunohistochemistry, A doxorubicin, T taxane, C cyclophosphamide, HR+ hormone receptor-positive, HER2− human epidermal growth factor receptor 2-negative, LN + lymph node-positive, NCT neoadjuvant chemotherapy, NET neoadjuvant endocrine therapy